38,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Rheumatoid arthritis is progressive, autoimmune inflammatory chronic disorder which do not have curative treatment yet. Aryl and hetero-aryl acids has maximum share of anti-inflammatory drugs in the therapeutics today as non steroidal anti-inflammatory drugs (NSAIDs). Benzimidazole moiety with heteroaryl and psudoacedic nature is promising moiety for development of NSAIDs. In the present project, synthesis, pharmacological evaluation, probable mechanism of action and quantitative structure-activity relationship (QSAR) of benzmidazole-2-carboxylic acids are reported. The excellent efficacy and…mehr

Produktbeschreibung
Rheumatoid arthritis is progressive, autoimmune inflammatory chronic disorder which do not have curative treatment yet. Aryl and hetero-aryl acids has maximum share of anti-inflammatory drugs in the therapeutics today as non steroidal anti-inflammatory drugs (NSAIDs). Benzimidazole moiety with heteroaryl and psudoacedic nature is promising moiety for development of NSAIDs. In the present project, synthesis, pharmacological evaluation, probable mechanism of action and quantitative structure-activity relationship (QSAR) of benzmidazole-2-carboxylic acids are reported. The excellent efficacy and safety was observed for benzimidaxole-2-carboxylic acid derivatives in laboratory animal models of inflammation and rheumatoid arthritis without side-effect of gastrointestinal disturbances. The reliving effects against pain and fever in experimental animal models suggested promise as potential NSAID.
Autorenporträt
Dr. Prasad Thakurdesai, completed his PhD in Pharmaceutical Sciences (Faculty of Medicine) and is a prolific pharmacologist.He has extensive experience in pharmacology research in industry as well as in academia. Other authors supervised the present project.